https://assets.capyfin.com/instruments/678fdc13234e27009c5d5a54.png avatar
Vertex
🇺🇸 NASDAQ:VRTX
•
Dec 31, 2024

Vertex Q4 2024 Earnings Report

Key Takeaways

Vertex Pharmaceuticals reported strong Q4 2024 results with a 16% increase in product revenue, reaching $2.91 billion, driven by the continued performance of TRIKAFTA/KAFTRIO. However, net income declined slightly due to increased R&D and SG&A expenses.

Total Revenue
$2.89B
Previous year: $2.52B
+14.7%
EPS
$3.98
Previous year: $4.2
-5.2%
Gross Profit
$2.49B
Operating Expenses
$1.87B
Effective Tax Rate
19.7%
Gross Profit
$2.49B
Previous year: $2.15B
+15.8%
Cash and Equivalents
$6.12B
Previous year: $11.2B
-45.5%
Free Cash Flow
$492M
Previous year: $177M
+178.8%
Total Assets
$23.1B
Previous year: $22.7B
+1.6%

Vertex Revenue

Vertex EPS

Vertex Revenue by Segment

Vertex Revenue by Geographic Location

Forward Guidance

Vertex expects continued revenue growth in 2025, driven by new product launches such as ALYFTREK and JOURNAVX, alongside further expansion of CASGEVY.

Positive Outlook

  • Expected full-year 2025 revenue of $11.75B to $12.0B
  • Continued strong demand for TRIKAFTA/KAFTRIO
  • Launch of ALYFTREK in the U.S. expected to drive revenue growth
  • Expansion of CASGEVY in multiple regions
  • Early contributions from JOURNAVX expected

Challenges Ahead

  • Higher R&D and SG&A expenses anticipated
  • Increased tax rates could impact profitability
  • Uncertainty regarding regulatory approvals in some regions
  • Potential market competition for CF and pain management drugs
  • Macroeconomic factors may affect international sales

Revenue & Expenses

Visualization of income flow from segment revenue to net income